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S U M M A R Y
Objectives: We investigated the antibody level of children against wild measles virus in view of recurrent
measles epidemics, in order to provide information on immunization status for health policies and for
the global measles mortality reduction initiative.
Methods: Two hundred and seventy-three children between the ages of 10 months and 13 years were
recruited for this study from three hospital facilities in south-west and north-central Nigeria. Serum
samples were collected from February to July 2009, and laboratory examination commenced in August of
the same year. Measles hemagglutinin (HA) antigen was prepared by culturing the measles vaccine virus
strain (Edmonston-Zagreb) in a vero/hSLAM cell line. Serum samples were treated to get rid of
potentiating factors, non-speciﬁc inhibitors, and agglutinins before the HA/hemagglutination inhibition
(HI) procedure.
Results: Out of the 175 children vaccinated in Ibadan, 60 (34.3%) had an antibody level not sufﬁcient to
protect against measles infection. Likewise, 12 (25.0%) vaccinated children from Ilorin had an antibody
level not sufﬁcient to protect against measles infection. There was no signiﬁcant difference in the level of
protection between the children in Ibadan and Ilorin (p > 0.05). The geometric mean titer (GMT) was
53.83 for males and 48.64 for females. There was no signiﬁcant difference between the GMTs of females
and males in both locations (p > 0.05). Also, no signiﬁcant difference was observed in the GMTs of
children in both locations (p > 0.05).
Conclusions: Of the vaccinated children, 157 (57.5%) developed protective measles virus HI antibody,
which is not enough to maintain protective herd immunity. Hence there is a need for catch-up and
follow-up vaccination programs, especially in rural areas and places with difﬁcult terrains, in order to
reduce measles mortality.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Measles is a major childhood problem and of serious concern in
Africa, Latin America, Europe, Southeast Asia, and the Eastern
Mediterranean.1 The Health Protection Agency (HPA) in the UK
revealed that 496 laboratory conﬁrmed cases were reported in
England and Wales up to the end of May 2011, surpassing the
annual 2010 total of 374 cases.2 In France, more than 7500 cases
were reported from January through March 2011. Cases have been
reported from 38 countries across the region, including outbreaks
in Spain, Serbia, Macedonia, and Turkey, among others. More than
10 000 cases were reported from countries in the European
Economic region in the ﬁrst 4 months of 2011.3* Corresponding author. Tel.: +234 803 467 6227.
E-mail address: bernardonoja@yahoo.com (A.B. Onoja).
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http://dx.doi.org/10.1016/j.ijid.2013.02.001In Africa, about 13 million cases and 650 000 deaths are
estimated to occur annually, and Sub-Saharan Africa to which
Nigeria belongs is one of the regions of the globe with the highest
measles morbidity and mortality.4 Despite the comprehensive
measles reduction strategy and partnership with the World Health
Organization (WHO), the United Nations Children’s Fund (UNICEF),
and other international organizations in Africa, certain high burden
countries continue to face recurrent epidemics.5 Nigeria has a high
childhood mortality rate, with measles being one of the leading
causes.6 Measles routine immunization has been low in Nigeria
and this has been responsible for the frequent measles outbreaks
observed in different parts of Nigeria. However, between 2005 and
2008, there was a general awakening on measles vaccination,
which culminated in an aggressive routine measles immunization
program with catch-up and follow-up vaccinations.
The objective of this study was to ascertain the level of
protection in children following the catch-up measles vaccinationses. Published by Elsevier Ltd. All rights reserved.
Table 1
Distribution of the immune status of children in the study population in selected
hospitals of Ibadan and Ilorin
Immune status Ibadan Ilorin Total
Protected 121 (59.0%) 36 (52.9%) 157 (57.5%)
Unprotected 84 (41.0%) 32 (47.1%) 116 (42.5%)
Total 205 (100.0%) 68 (100.0%) 273 (100.0%)
Table 2
Distribution of the vaccination status of children with respect to immune status
Vaccination status/immune status Ibadan Ilorin
Vaccinated
Protected 115 (65.7%) 36 (75.0%)
Unprotected 60 (34.3%) 12 (25.0%)
Total 175 (100.0%) 48 (100.0%)
Nonvaccinated
Protected 6 (20.0%) 0 (0.0%)
Unprotected 24 (80.0%) 20 (100.0%)
Total 30 (100.0%) 20 (100.0%)
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the southern and northern states, respectively) and the nationwide
follow-up campaign in 2008.
2. Materials and methods
2.1. Study design
Three hospitals were chosen for this study: Adeoyo
Maternity Teaching Hospital and Oni Memorial Children’s
Hospital, both in Ibadan, Oyo State (south-west), and Abanise-
lolu Children’s Hospital in Adeta–Ilorin, Kwara State (north-
central). This study was conducted in two states of the
federation between February and July 2009. This was done
to compare the immune status of children in parts of south-
west and north-central Nigeria.
2.2. Study population
A total of 273 children between the ages of 10 months and 13
years, from different socio-economic backgrounds, were recruited
into the study. Of the 205 (75.1%) children from Ibadan, 99 (36.3%)
were from Adeoyo Maternity Teaching Hospital and 106 (38.8%)
from Oni Memorial Children’s Hospital. Sixty-eight (24.9%)
children were from Abanise-lolu Children’s Hospital. Informed
parental consent was sought before a blood sample was collected.
Details of the vaccination history were obtained through
questionnaire and/or from parental recall. The ﬁrst dose of measles
vaccine is given at 9 months, with a booster dose expected at 12–
15 months of age, but this is usually ignored. The actual age at
which individual children were subsequently vaccinated was not
recalled by their parents.
2.3. Sample collection and handling
Between 3 and 5 ml of blood were collected in plain tubes
through venipuncture. The blood was allowed to clot and was
centrifuged at 3000 rpm for 10 min. Serum was carefully
removed with a Pasteur pipette and transferred to sterile
labeled cryovials. These were labeled with a sample identiﬁca-
tion number, date of collection, and specimen type and were
then stored at 20 8C until the representative sample size was
obtained.
2.4. Virus culture
The measles virus hemagglutinin antigen (MV HA Ag) was
prepared from the Edmonston-Zagreb vaccine strain obtained
from the Public Health Centralized Immunization Clinic of the
University College Hospital, Ibadan. The vaccine was manufac-
tured by the Serum Institute of India Ltd (Pune, India). Growth and
maintenance media were made from Eagle’s minimum essential
medium (Sigma-Aldrich, USA) supplemented with 10% and 2%
fetal calf serum, respectively. A vero/hSLAM cell line was grown in
two T75 ﬂasks and inoculated with 0.4 ml of reconstituted
measles vaccine virus. These are vero cells that have been
transfected with a plasmid encoding the gene for the human
signaling lymphocyte activation marker (hSLAM).7 On the ﬁfth
day post-inoculation, the cells were harvested after the cytopathic
effects (CPE) of stellate bodies and syncytia were observed. The
polyethylene glycol (PEG) method of virus puriﬁcation was
carried out overnight at +4 8C and then 5 ml of tween80 detergent
was added on ice and vigorously shaken. Two milliliters of ether
were added and spun for 20 min at 3000 rpm in a cold centrifuge.
Puriﬁed MV HA Ag was collected from the interphase and tested
for hemagglutination activity.8–112.5. Hemagglutination inhibition assay (HIA)
The hemagglutination test was ﬁrst carried out using the MV
HA Ag to obtain 1 HA unit, from which the 4 HA units (standard
working concentration) was obtained. The 1 HA titer was 320. The
HIA was then performed by a modiﬁcation of the method used by
Gershon and Krugman.12 Serum was heat-inactivated at 56 8C for
30 min to get rid of complements and potentiating factors. Non-
speciﬁc inhibitors of hemagglutination and non-speciﬁc aggluti-
nins were removed from test sera by the addition of 0.1 ml of each
serum to 0.4 ml borate saline and 0.5 ml of a 25% suspension of acid
washed kaolin. The mixture was spun at 1200 rpm for 10 min, and
25 ml of packed patas monkey (Erythrocebus patas) erythrocytes
was added to remove non-speciﬁc agglutinins. Two serial dilutions
of the treated sera were done starting from 1:10 through 1:320.
Then 0.025 ml of 4 HA units of antigen was added to each well of
the serially diluted sera in U-bottom 96-well microtiter plates.
Each well received 0.025 ml of a 0.5% suspension of monkey
erythrocytes. Plates were shaken and incubated for 1 h at 36 8C.
Complete inhibition of agglutination at 1:40 dilution of serum was
considered as the protection level.8,13,14 Serum from a previously
vaccinated individual was used as control.
2.6. Statistical analysis
Statistical analysis was carried out with SPSS version 20.0 to
test for equality of the means using the independent t-test.
3. Results
In this study, 157 (57.5%) children were found to be protected
and 116 (42.5%) were found to be unprotected, as shown in Table 1.
Two hundred and twenty-three (81.7%) children were vacci-
nated and 50 (18.3%) were not. Out of the 205 children from
Ibadan, 175 (85.4%) were conﬁrmed to be vaccinated, while 48
(70.6%) were vaccinated in Ilorin (Table 2). Out of the 175 children
vaccinated in Ibadan, 60 (34.3%) had an antibody level not
sufﬁcient to protect against measles infection. Likewise, 12 (25.0%)
children vaccinated in Ilorin had an antibody level not sufﬁcient to
protect against measles infection (Table 2). There was no
signiﬁcant difference in the level of protection between children
in Ibadan and Ilorin (p > 0.05).
The mean age of children was 4.2  2.7 years for females and
4.7  2.5 years for males. The mean age of male and female children
was not signiﬁcantly different in both locations (p > 0.05). One
Table 3
Distribution of measles virus hemagglutination inhibition titers according to the
gender of the children at selected hospitals in Ibadan and Ilorin, Nigeria
Variables Ibadan Ilorin Combined
GMT
Males 51.44 60.54 53.83
Females 49.70 45.16 48.64
MV HI titer
10 43 (20.9%) 23 (33.8%) 66 (24.2%)
20 41 (20.0%) 9 (13.2%) 50 (18.3%)
40 58 (28.3%) 18 (26.5%) 76 (27.8%)
80 47 (22.9%) 8 (11.8%) 55 (20.1%)
160 13 (6.3%) 7 (10.3%) 20 (7.3%)
320 3 (1.5%) 3 (4.4%) 6 (2.2%)
Total 205 (100%) 68 (100%) 273 (100%)
Gender
Males 104 (50.7%) 37 (54.4%) 141 (51.6%)
Females 101 (49.3%) 31 (45.6%) 132 (48.4%)
Total 205 (100.0%) 68 (100.0%) 273 (100.0%)
GMT, geometric mean titer; MV, measles virus; HI, hemagglutination inhibition.
Table 4
Frequency distribution of the age of children at selected hospitals in Ibadan and
Ilorin, Nigeria
Age group Ibadan Ilorin Combined
<1 year 9 4 13
1–5 years 137 37 174
>5 years 59 27 86
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(49.3%) were females, while 37 (54.4%) of the children from Ilorin
were males and 31 (45.6%) were females, as shown in Table 3.
There was no signiﬁcant difference in the geometric mean titer
(GMT) of male and female children in each location and both
locations combined (p > 0.05). One hundred and seventy-four
(63.7%) children in the study were between 1 and 5 years of age, 13
(4.8%) were aged less than 1 year, and 86 (31.5%) were older than 5
years, with the oldest being 13 years of age, as shown in Table 4.
4. Discussion
This study examined the level of measles hemagglutinating
antibody in children in three selected hospitals in the south-west
and north-central geopolitical regions of Nigeria. The HIA is a
classical technique that has been employed in prevalence studies
and has good correlation with ELISA and neutralization techniques.
It reﬂects the real level of the population’s antibodies.15
Results obtained in this study show that a large percentage of
children aged under 5 years in the two states studied were not
protected from measles infection. This is a matter of concern, as
this age group is an indication of the vulnerability of children to
measles infection. Measles is the ﬁfth major cause of childhood
mortality in Nigeria.6 Of particular interest in this study is the
relatively large number of vaccinated children in both states and
locations who were found not to be protected. While this could be
as a result of secondary vaccine failure, it could also be due to
unsubstantiated wrong information from parents and guardians
about the true vaccination status of their children. There was no
signiﬁcant difference in the level of protection between the
children in Ibadan and Ilorin (p > 0.05). We also observed in this
study that the antibody level rose according to the age of the
children. This is in agreement with the study of Sakata and
Sugiura16 who showed that the level of antibody directed against
the hemagglutination protein was 1:32 for the ﬁrst weeks of
infection, which increased to 4:32 over several years (dilution
factor 8 as against our dilution factor 10). There was no signiﬁcant
difference in the GMTs of males and females in the two locations.
Our observations in this study showed that children with a
previous infection from a past epidemic developed a high antibody
proﬁle, with titers as high as 1:160. Hamid and colleagues
observed that the number of protected-unprotected children with
a high antibody level was higher in those parts of Nigeria where
there had been measles epidemics.17 Measles has been known to
confer life-long immunity post infection.18Table 2 shows that of the 273 children studied, 175 (85.4%) and
48 (70.6%) were vaccinated in the selected hospitals in Ibadan
(south-west) and Ilorin (north-central) geopolitical regions. This is
in agreement with vaccination coverage of 71–82% also reported
nationally.19
This was a retrospective study. The immune response in this
study may be due to routine vaccination, or the catch-up
vaccination of 2005 and 2006, as well as follow-up of 2008. It
may therefore be inferred that the remarkable level of protection
observed in this study may be the after-effect of the campaign. As
shown in Table 2, only six (12.0%) of the unvaccinated children
were protected as a result of recovery from natural infection.
Further studies are needed to conﬁrm this. In this study, we
observed that 50 (18.3%) and 66 (24.2%) children had unpro-
tective titers of 20 and 10, respectively (Table 3). This could be
due to vaccine failure due to a break in the cold chain, or
malnutrition. Past studies have shown that a break in the vaccine
cold chain results in the inability to develop measles protective
antibodies.20
In conclusion, measles immunization can serve as a proxy
indicator for access to basic health services for children aged <5
years.21 We recommend that routine measles vaccination be
improved in Nigeria in order to reduce the incidence of measles
outbreaks.
4.1. Challenges
This study was carried out after the National Programme on
Immunization (NPI) vaccination campaign, so we could not
conduct a pre-NPI sero-survey. We had a small number of
serum samples from Ilorin, Kwara State because we could not
collect them ourselves due to distance and logistics problems.
We lacked materials to embark on a more sophisticated and
modern laboratory technique (plaque reduction virus neutral-
ization) so we relied on the HA/HI technique having expended
a lot of resources in a resource-limited country. We received no
grant or ﬁnancial assistance whatsoever, but used personal
funds.
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